(Reuters) – Merrimack Pharmaceuticals Inc said its lead experimental cancer drug when used as a combination improved the overall survival rate in patients with metastatic pancreatic cancer, doubling its shares in premarket trading.
Merrimack said a combination of its drug, MM-398, and…
Merrimack cancer drug combination improves survival in study
No comments:
Post a Comment